论文部分内容阅读
目的探讨联合应用聚乙二醇化干扰素-α与肿瘤选择性化疗药卡培他滨抑制肝癌生长的作用。方法用30只LCI-D20人肝癌高转移裸鼠模型,随机分为对照组、聚乙二醇化干扰素- α组(1．875μg／周)、卡培他滨组(每日2．10mmol／kg体重)和联合用药组。用药4周后,观察裸鼠肝内移植瘤体积变化及肝内转移情况,检测血常规、肝肾功能和体重变化。结果对照组、聚乙二醇化干扰索-α组、卡培他滨组和联合用药组肿瘤体积分别为(2 275±1 337)、(336±220)、(889±614) 和(26±56)mm~3。与对照组相比,用药组肿瘤体积明显缩小,联合用药组尤为突出(P<0．01)。各用药组血常规、肝功能和体重的变化差异无统计学意义(P>0．05)。结论聚乙二醇化干扰素-α与卡培他滨联合应用能显著抑制LCI-D20裸鼠模型中肝移植瘤的生长和浸润,副作用不明显。
Objective To investigate the effect of combined use of pegylated interferon-α and capecitabine, a tumor-selective chemotherapeutic drug, on the growth of hepatocellular carcinoma. Methods Totally 30 LCI-D20 human hepatocellular carcinoma (HCC) nude mice model were randomly divided into control group, peginterferon alfa group (1.875μg / week), capecitabine group (2.10mmol / kg body weight) and combination group. After 4 weeks of treatment, the changes of intrahepatic xenograft tumor volume and intrahepatic metastasis in nude mice were observed. The changes of blood routine, liver and kidney function and body weight were observed. Results The tumor volumes in the control group, pegylated interferon-α group, capecitabine group and combination group were (2 275 ± 1 337), (336 ± 220), (889 ± 614) and (26 ± 56) mm ~ 3. Compared with the control group, the tumor volume of the treated group was significantly reduced, particularly in the combination group (P <0.01). There was no significant difference in blood routine, liver function and body weight in each medication group (P> 0.05). Conclusion Pegylated interferon-α combined with capecitabine can significantly inhibit the growth and infiltration of liver xenografts in LCI-D20 nude mice model with no obvious side effects.